News
Find the latest news about Inaphaea BioLabs here
-
Meet the Inaphaea collaborator: DefiniGEN
Inaphaea BioLabs’ collaboration partner DefiniGEN provides technology to revolutionise liver models for drug efficacy and toxicology screening, utilising a platform that enables the large-scale generation of hepatocyte-like cells (Opti-HEP) with comparable functionality…
-
Meet the Inaphaea collaborator: HistologiX
HistologiX is a leading GLP/GCP compliant CRO supporting tissue-based evaluation of biomarkers. The company’s experienced scientific team provides specialist histology, immunohistochemistry (IHC), immunofluorescence (IF), and in situ hybridisation (ISH) services including multiplex assay…
-
Supporting translational drug development for gynaecological oncology
In recognition of Gynaecological Cancer Awareness Month, the Inaphaea team explores the potential of patient derived cells for gynaecological cancers.
-
Inaphaea wins contract with US biotech
Inaphaea BioLabs is pleased to confirm the execution of a revenue-bearing contract for the provision of patient derived oncology cell (PDC) based services with a US biotech company. The contract is a…
-
BIO 2024 round-up
From 3 to 6 June 2024, Inaphaea’s Head of Strategic Development, Dr Andrew Carnegie and our Scientific Consultant, Dr Mark Eccleston attended the BIO International Convention in San Diego with our partners…
-
Inaphaea BioLabs: one year on
This month marks one year since Inaphaea BioLabs launched. In this blog, Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, describes how Inaphaea has grown and developed during its first…
-
Inaphaea news round-up: March 2024
This news round-up covers our updates from March. BioEurope was a key highlight, with our commercial team conducting over 60 meetings and spreading the word about Inaphaea to the wider market. To…
-
Meet the commercial team: Inaphaea BioLabs
Inaphaea prides itself on conducting science that is reproducible, human-relevant, and translatable to ensure efficient progress through discovery and preclinical development. Patient-derived cells (PDCs) are at the heart of Inaphaea’s work and…
-
Patient-derived cells (PDCs): the future of drug discovery
Drug discovery is known for its high attrition rates that lead to significant investments of both cost and time. But the emergence of patient-derived cells (PDCs) is on track to revolutionise this…
-
Inaphaea news round-up: January & February 2024
This news round-up covers our updates and highlights from January and February. It has been a busy start to the year for Inaphaea with events, a new collaboration, and progress in the…